Literature DB >> 20017749

Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine).

D W Dodick1.   

Abstract

A number of comorbid disorders, behavioural traits and associated risk factors in patients with migraine are known to increase the risk of complications such as ischaemic vascular events and chronic migraine, a syndrome that is more disabling and resistant to treatment with acute and preventative medications than episodic migraine. Reduction of cardiovascular risk factors, smoking cessation and use of non-oestrogen-containing oral contraceptives in female patients are beneficial strategies to reduce the risk of ischaemic events in patients with migraine (especially those with aura). Attack frequency, acute medication overuse, obesity and coexisting depression and anxiety disorders are particularly strong but potentially modifiable independent risk factors for progression to chronic migraine. Identifying and managing comorbidities and associated risk factors for complications of migraine are likely to require an integrated disease management strategy involving several disciplines and allied health services. Such a disease-oriented model of care may potentially interrupt the cycle of progression and disability and improve quality of life for patients with migraine.

Entities:  

Mesh:

Year:  2009        PMID: 20017749     DOI: 10.1177/03331024090290S303

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  15 in total

1.  Diagnosis of acute headache.

Authors:  Stephanie J Nahas
Journal:  Curr Pain Headache Rep       Date:  2011-04

2.  Correlation Between Life Events and Quality of Life in Patients with Medication-Overuse Headache.

Authors:  Ebru Altintaş; Başak Karakurum Göksel; Nilgün Taşkintuna; Çağla Saritürk
Journal:  Noro Psikiyatr Ars       Date:  2015-07-07       Impact factor: 1.339

Review 3.  Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients.

Authors:  Licia Grazzi; Eleonora Grignani; Domenico D'Amico; Emanuela Sansone; Alberto Raggi
Journal:  Curr Pain Headache Rep       Date:  2018-08-27

4.  Bariatric Surgery Promising in Migraine Control: a Controlled Trial on Weight Loss and Its Effect on Migraine Headache.

Authors:  Soodeh Razeghi Jahromi; Maryam Abolhasani; Zeinab Ghorbani; Solmaz Sadre-Jahani; Zahra Alizadeh; Mohammad Talebpour; Alipasha Meysamie; Mansoureh Togha
Journal:  Obes Surg       Date:  2018-01       Impact factor: 4.129

5.  Brain structural properties predict psychologically mediated hypoalgesia in an 8-week sham acupuncture treatment for migraine.

Authors:  Jixin Liu; Junya Mu; Qianqian Liu; Wanghuan Dun; Ming Zhang; Jie Tian
Journal:  Hum Brain Mapp       Date:  2017-06-13       Impact factor: 5.038

Review 6.  Migraine With Comorbid Depression: Pathogenesis, Clinical Implications, and Treatment.

Authors:  Nailah Asif; Apurva Patel; Deepanjali Vedantam; Devyani S Poman; Lakshya Motwani
Journal:  Cureus       Date:  2022-06-16

Review 7.  Migraine: maladaptive brain responses to stress.

Authors:  Nasim Maleki; Lino Becerra; David Borsook
Journal:  Headache       Date:  2012-10       Impact factor: 5.887

8.  Changes in MIDAS, Perceived Stress, Frontalis Muscle Activity and Non-Steroidal Anti-Inflammatory Drugs Usage in Patients with Migraine Headache without Aura following Ayurveda and Yoga Compared to Controls: An Open Labeled Non-Randomized Study.

Authors:  M S Vasudha; N K Manjunath; H R Nagendra
Journal:  Ann Neurosci       Date:  2018-09-11

9.  Stress in migraine: personality-dependent vulnerability, life events, and gender are of significance.

Authors:  Kerstin Hedborg; Ulla Maria Anderberg; Carin Muhr
Journal:  Ups J Med Sci       Date:  2011-06-14       Impact factor: 2.384

10.  Polymorphism of the Glutamate Transporter Protein EAAT2 and Migraine Transformation into Chronic Daily Headache.

Authors:  Hae-Eun Shin; Soo-Jeong Han; Kwang-Soo Lee; Jeong-Wook Park
Journal:  J Clin Neurol       Date:  2011-09-29       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.